After its efficacy was demonstrated in a clinical trial, the US Food and Drug Administration approved a new treatment options for adult patients with 2 types of poor-prognosis acute myeloid leukemia.
The US Food and Drug Administration recently approved a new treatment option for patients with relapsed or refractory acute myeloid leukemia who have IDH2 mutations.
